PetVivo to Exhibit Spryng with OsteoCushion™ Technology at the Veterinary Meeting and Expo Conference in Orlando, Florida on January 25-29, 2025
14. Januar 2025 09:29 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, Jan. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of medical devices and biomedical therapeutics for equines and companion animals...
PETVIVO HOLDING, INC. ANNOUNCES PARTNERSHIP ENGAGEMENTS WITH VEDCO, INC. AND CLIPPER DISTRIBUTING, LLC
10. Januar 2025 09:45 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) ("PetVivo"), a pioneering biomedical technology company focused on adapting human biotech, medical...
Nutriband Issues Letter to Shareholders
31. Dezember 2024 07:00 ET
|
Nutriband Inc.
CEO Publishes Letter to Shareholders looking over achievements in 2024 and outlook for 2025
PETVIVO HOLDINGS, INC. TO HOST SHAREHOLDERS UPDATE MEETING ON JANUARY 8, 2025
30. Dezember 2024 10:23 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Dec. 30, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical...
Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology
27. Dezember 2024 09:25 ET
|
Nutriband Inc.
Chinese Patent for AVERSA extended to Macao
PetVivo to Exhibit Spryng with OsteoCushion™ Technology at the American Association of Equine Practitioners Convention on December 8-10, 2024
26. November 2024 15:00 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, Nov. 26, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of medical devices and biomedical therapeutics for equines and companion animals,...
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study
18. November 2024 08:45 ET
|
Dogwood Therapeutics, Inc.
- IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue and sleep disturbance as compared to placebo...
PetVivo Reports Fiscal Q2 2025 Results
14. November 2024 16:00 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Nov. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and...
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2024
11. November 2024 10:07 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Nov. 11, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical...
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results
07. November 2024 07:05 ET
|
Dogwood Therapeutics, Inc.
- Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) formed in October by combination of Virios Therapeutics, Inc. and Pharmagesic (Holdings) Inc., 100% parent company of Wex Pharmaceuticals, Inc. (the...